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Abstract
The immune system poses obstacles to viral vectors, even in the first administration to preimmunized hosts. We have
observed that the livers of B cell-deficient mice were more effectively transduced by a helper-dependent adenovirus
serotype-5 (HDA) vector than those of WT mice. This effect was T-cell independent as shown in athymic mice. Passive
transfer of the serum from adenovirus-naı¨ve WT to Rag1KO mice resulted in a reduction in gene transfer that was traced to
IgM purified from serum of adenovirus-naı¨ve mice. To ascribe the gene transfer inhibition activity to either adenoviral
antigen-specific or antigen-unspecific functions of IgM, we used a monoclonal IgM antibody of unrelated specificity. Both
the polyclonal and the irrelevant monoclonal IgM inhibited gene transfer by the HDA vector to either cultured
hepatocellular carcinoma cells or to the liver of mice in vivo. Adsorption of polyclonal or monoclonal IgMs to viral capsids
was revealed by ELISAs on adenovirus-coated plates. These observations indicate the existence of an inborn IgM mechanism
deployed against a prevalent virus to reduce early post-infection viremia. In conclusion, innate IgM binding to adenovirus
serotype-5 capsids restrains gene-transfer and offers a mechanism to be targeted for optimization of vector dosage in gene
therapy with HDA vectors.
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Introduction
The immune system poses an important obstacle for the success
of gene therapies with viral vectors [1,2]. Conceivably, the
immune system has evolved to fight prevalent microbial intruders
which are often used as vehicles for therapeutic transgenes.
Hepatotropic gutless or helper-dependent adenovirus serotype-5
(HDA) vectors are, in principle, ideal candidates to correct inborn
metabolic diseases by reintroducing a correct version of the gene
into hepatocytes [3–5] or by taking over the liver as a biofactory to
produce a deficient plasmatic protein [6]. HDA vectors are praised
for their capacity to accommodate long transgenes and for their
low immunogenicity due to the absence of any viral protein from
their genome with the exception in the administered packaging
capsids.
Innate immunity neutralizes 90% of adenoviral particles within
24 hours following intravenous vector administration [1]. This is
considered to be the result of innate up-regulation of interferons
and other inflammatory cytokines via Toll-like receptor–depen-
dent and -independent pathways [7–10] as well as clearance by
macrophages [11]. The complement system also plays a role in
adenoviral vector opsonization and clearance as a part of the
innate immune system [12,13]. IgM natural antibodies serve as a
potent complement activators.
The intensity of the inflammatory innate immune response to
adenoviral vectors is activated in a dose-dependent manner [1,14–
17]. To improve both safety and feasibility of HDA-mediated gene
therapy, strategies to prevent the cytokine-mediated acute toxic
response [18] or to reduce as much as possible the required viral
doses are badly needed [6,19–23].
Natural antibodies, predominantly IgM, provide a first line of
immune defense following infection, prior to the generation of
adaptive, high-affinity humoral responses. IgM is the second most
abundant immunoglobulin in serum (in the range of 1–2 mg/ml)
and is the dominant subtype in early humoral immune responses
[24]. Since in most instances these immunoglobulins have not
undergone affinity maturation through somatic hypermutation,
they rely on a pentameric structure to increase valency and hence
avidity for antigen [25,26]. Thus, IgM is 100 to 10,000 times more
effective than IgG in mediating agglutination. Some of the IgMs
present in the serum have been produced in a T helper-
independent manner and can be present even without previous
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exposure to cognate antigen such as those against A and B blood
group antigens [27,28]. These natural antibodies probably occur
because of crossreactions with microbial flora antigens [27].
Furthermore, IgMs have been reported to bind and hamper
infection by adenoviruses in an apparently antigen-independent
fashion [29]. Moreover, an example of rat IgM promiscuously
binding carboxyterminal ends in bacterial phages [30] has been
described. IgM is able to activate the classical activation pathway
of complement and thus opsonize and maybe destroy virions. An
emerging picture is that IgMs may contribute to a first line of
defense because they promiscuously reduce the efficiency of
infection by a number of virus species before specific immunity has
been developed, thus reducing viremia upon viral entry and
during the first rounds of viral replication.
IgM, as well as the majority of natural antibodies, are
polyreactive and bind to a number of different antigens with low
affinity (Kd = 1024 to 1027 M). However, their low affinity to
adenovirus 5 is partly compensated for by its high avidity due to
pentameric structure. While the pentameric IgM demonstrated
strong binding to the adenovirus capsid, monomeric IgG shows
weak binding to adenovirus 5 [29]. Indeed, there is evidence for
complement factor C3 activation during the elimination of
adenovirus 5 by Kupffer cells [29].
It has been reported that coagulation factor X binds to the
adenovirus 5 hexon via an interaction between the factor X Gla
domain and the hypervariable regions of the hexon capsid protein
[31]. The formation of this complex was found to be essential for
transduction of the livers of mice, but factor X was not required for
liver transduction in mice that lack antibodies. In a recent report
[32], the ability of the first generation adenoviral serotype-5
capsids to bind factor X of coagulation has been shown to inhibit
complement deposition and viral inactivation upon exposure to
IgM. Non-immune IgM was found to directly bind to adenovirus 5
capsids [29]. IgM was prevented from activating complement by
the clotting factor X without involvement of the protease activity
of this complement factor [32]. Deficiency in factors of the classical
complement activation route or complement depletion with cobra
venom toxin reestablished gene transfer levels in the absence of
coagulation factor X [32]. Previous reports [33–35] had demon-
strated that in the absence of immunoglobulins, as occurs in Rag-
deficient mice, there was a notorious increase in liver gene transfer
by serotype-5 first generation adenovirus. A more recent work [11]
showed that partial reconstitution of IgM in Rag deficient mice
resulted in significant reductions in liver transduction by adeno-
virus 5 but not an adenoviral 5 vector engineered with the hexon
from adenovirus capsid 6.
In this study we found that non-immune serum IgM is critical
for reducing the efficiency of HDA vectors to mediate liver gene
transfer. This is the result of an innate IgM function, which is
apparently unrelated to its well described adaptive immunity
functions.
Materials and Methods
Ethics Statement
Experimental protocols were performed according to European
Council Guidelines. Acceptable standards of humane animal care
and treatment employed in these mice (ref. no. CEEA069-10,
CEEA068-10 and CEEA034-10) and the experimental design of
this study (study number CEEA029/09 and CEEA022/13) were
approved by the Ethics Committee for Animal Testing of the
University of Navarra.
Mice strains
Rag12/2 B6 (B6.129S7-Rag1tm1Mom/J, hereafter B6.Rag1KO),
Rag12/2 BALB/C (C.129S7(B6)-Rag1tm1Mom/J, hereafter
Rag1KO) and Rag22/2IL-2Rc2/2 BALB/C (BALB/c-
Rag2tm1Fwa II2rctm1Wjl, hereafter Rag2KO) transgenic mice were
obtained from Jackson Laboratories (Bar Harbor, Maine USA).
Female BALB/C WT and athymic (Hsd:Athymic Nude-Foxn1nu)
mice of 6–8 weeks-old were purchased form Harlan Interfauna
Iberica (Spain). mMT (B6.129S2-Ighmtm1Cgn/J, hereafter
B6.mMT) female mice were kindly provided by Claude Leclerc
(Institut Pasteur, Paris, France) and Stephanie Hughes (University
of Geneva, Switzerland).
Production of HDA vectors
The expression cassette of HDA vector contains the firefly
luciferase gene under the control of the liver-specific human a-1-
antitrypsin promoter with regulatory sequences from the human
albumin enhancer. We also produced a second HDA vector
expressing the optimized human cDNA of the housekeeping
porphobilinogen deaminase (hPBGD) isoform directed by the same
promoter. Construction and production of HDA vectors were
performed as detailed elsewhere [23]. HDA-luciferase production
had 2.1561012 viral particles (vp)/ml as measured by spectropho-
tometry. Quantification of infective units (iu) was performed in the
Huh7 cell line as detailed elsewhere [36]. The iu/vp ratio was
estimated at 1/417. HDA-hPBGD production had 561012 vp/ml
and 2.561010 infective units (iu)/ml. A dose of 561010 vp/mouse
intravenously injected (iv) was used for all the in vivo experiments
unless specified. Helper contamination was lower than 0.0001% in
both productions.
Detection of transgene expression
Non-invasive luciferase expression measurements were per-
formed in living mice 2 days after HDA administration, as
previously described [37]. Then, mice were sacrificed and DNA
was extracted from liver samples using the Qiamp DNA kit
(Qiagen). Liver gene transfer was analyzed by real time QPCR for
detection of the 39UTR-polyA region of the vector using specific
primers (pHDAfw 59-GCTAGCCTTTGAATGTAACCA-39,
pLUCrv 59-ACACCTTCAGAACTGGTTTATTAGT-39). Nor-
malization to genomic DNA was performed using specific primers
for murine GAPDH (GAPDHfw: 59-CCAAGGTCATCCATGA-
CAAC-39; GAPDHrv: 59-GCTCATTTCCTGGTATG-39).
QPCR was performed in an iQ5 real-time PCR detection system
(Bio-Rad, Hercules, CA) using iQ SYBR green supermix. PCR
amplification conditions were as follows: 95uC for 5 min, 40 cycles
of 95uC for 15 sec, 60uC for 15 sec, 72uC for 25 s and 80uC for 10
s; and a final extension for 10 min at 72uC). The amount of each
transcript was expressed according to the formula 2Ct(GAPDH)-
Ct(luciferase), where Ct is the cycle at which the fluorescence rises
appreciably above background fluorescence.
Luciferase activity was also analyzed in liver homogenates using
a luciferase assay kit (Promega) and a tube luminometer (Lumat
LB 9507; Berthold Technologies, Bad Wildbad, Germany), as
described elsewhere [37].
Liver expression of the PBGD transgene was measured by
enzymatic activity [23] and by real-time QPCR for detection of
the 39UTR-poly region of the vector using the specific primers
(pHDAfw 59-GCTAGCCTTTGAATGTAACCA-39; pPBGDrv
59-CCTTCAGAACTGGTTTATTAGTAGG-39). Normaliza-
tion to genomic DNA was performed as detailed above.
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Antibodies
Polyclonal serum IgG were purchased from Sigma (ref: I5381)
while polyclonal IgM were purified from BALB/c WT serum.
Briefly, serum pools from 30 mice were chromatographed on a
PD-10 column equilibrated with binding buffer (following GE
Healthcare protocol instructions, Uppsala Sweden). Then, collect-
ed fractions with IgM were chromatographed on HiTrap IgM
Column (GE Healthcare); after extensive washing IgMs were
eluted according to manufacturer’s instructions. The IgM batches
were passed again through a PD-10 column equilibrated with PBS
and eluted fractions chromatographed over protein A and protein
G affinity columns. Non bound antibodies, corresponding to IgMs
were collected and concentrated through 100.000 MWCO
Ultracel YM-100 Centricons (Millipore, USA). Recovered IgM
were finally dialyzed overnight in PBS at 4uC. The final
concentration was 1.45 mg/mL as determined on a NanoDropH
ND-1000 Spectrophotometer at 280 nm with an extinction
coefficient of 1.18.
Monoclonal IgG and IgM were obtained from mouse hybrid-
omas that respectively specifically recognized human interferon
alpha 5 and human AE2 anion exchanger [38] (GenBank:
AAC50964.1). Hybridomas were grown in RPMI-1640 media
supplemented with 10% fetal bovine serum (Ultra Low IgG;
GIBCO; Cat No. 16-250-078), antibiotics, L-glutamine, Sodium
Pyruvate and non-essential aminoacids. Once hybridoma cells
were optimally expanded in order to eliminate bovine contami-
nants from the final product, the percentage of fetal bovine serum
in the culture medium was progressively reduced to 5% and
three days before collecting the culture supernatant, hybridoma
cells were washed with phosphate buffered saline and cultured in
serum-free medium. This ensures that there is no contaminant
bovine IgM in the final product. Then, antibodies in the
supernatant were precipitated with ammonium sulphate, resus-
pended and dialyzed in sodium phosphate pH 7. Immunoglobu-
lins were then captured on Ceramic Hydroxyapatite, washed and
eluted with a phosphate gradient. The eluted antibodies were
passed through a protein G column. To recover the IgG, the
protein G column was washed with phosphate buffered saline
pH 7.4 and IgGs were eluted with Citrate Buffer pH 2.7 and
neutralized with 1M Tris pH 9. For IgM recovery, the protein G
column was dialyzed in 100 mM sodium acetate buffer pH 5.5.
Then, collected fractions with IgM were injected into a CM
Ceramic Hyper D cation exchange column (Pall Life Sciences),
washed and eluted with increasing sodium chloride concentra-
tions. Citrate buffer (IgG) or acetate buffer (IgM) were changed to
saline through a PD-10 gel exclusion chromatography column,
fractions pooled, and filtered through a 0.2 mm filter. Finally,
immunoglobulins were dialyzed overnight in PBS at 4uC. The
final monoclonal concentration was 1.57 and 1.2 mg/mL for IgM
and IgG, respectively. The purity of each antibody was
determined by running aliquots on a denaturing gel (SDS-PAGE)
without reducing agents followed by Coomassie blue staining
(figure not shown).
B cell depletion
Antimouse-CD20 (kindly provided by Genentech, CA) was i.v.
administered in Female BALB/C WT mice 15 and 5 days before
HDA at a dose of 250 ug. To check B cell depletion, mice blood
samples were stained for 10 minutes with anti-CD19-PE and
FcBlock (BD Pharmingen, San Agustı´n de Guadalix, Spain) and
erythrocytes lysed with FACS lysing solution (BD Biosciences, San
Agustı´n de Guadalix, Spain). FACSCalibur (BD-Biosciences, San
Agustı´n de Guadalix, Spain) was used for cell acquisition and data
analysis was carried out using FlowJo software (Tree Star Inc.,
Olten, Switzerland).
ELISA
Ninety-six-well plates were coated at 4uC overnight with 36109
vp of HDA-luciferase vector in bicarbonate buffer, pH 9.5. After
washing 5 times with 2% bovine serum albumin (BSA) in PBS,
plates were blocked with 2% BSA in phosphate-buffered saline for
3 hours and a half at RT. Plates were washed 10 times in washing
buffer (phosphate-buffered saline +0.05% Tween20) and incubat-
ed for 2 h and a half at 4uC with 10 mg/ml of each mono- or
polyclonal purified immunoglobulins (immunoglobulin added to
reaction 1 mg) diluted in assay diluent (phosphate-buffered saline
+2% BSA +0.05% Tween20). 10 ml of serum from WT or
Rag1KO mice were diluted 1/10 in assay buffer. Plates were
washed 106 in washing buffer and then incubated for 2 h at 4uC
with horseradish peroxidase (HRP)-conjugated goat anti-mouse
IgM (1:4000; Pierce, Rockford, IL, USA) or anti-mouse IgG
(1:4000; Pierce, Rockford, IL, USA) antibodies at 0.2 mg/ml
diluted in assay diluent. For all ELISAs, HRP was detected with
tetramethylbenzidine. The same ELISA setting without HDA
coating was used to detect and subtract the background signal.
This technique with modifications has been previously described
by R. Khare et al [11].
In vitro Huh7 cells transduction
Huh7 cells were seeded in regular 6-well cell culture plates at a
density of 56105 cells per well. Twenty-four hours later, 5 mg of
the different immunoglobulins or 20 ml of WT serum were
incubated with HDA-luciferase (MOI 50.000) for 30 min at 37uC
with shaking. Then, Huh7 cells were treated with each Ig-vector
mix and incubated all together for 4 h at 37uC in DMEM 2%
heat-inactivated fetal bovine serum (Ultra Low IgG; GIBCO) in a
total volume of 300 ml. Cells were then washed 3 times with saline,
harvested and viral DNA was extracted using the Viral DNA
extraction kit (Roche).
Statistical analysis
Samples were run in duplicate or triplicate. The results were
plotted as interquartile range (box) and extreme values (whisker).
Statistical analyses in in vivo assays were performed using the
Kruskal–Wallis non-parametric ANOVA. Post hoc pairwise com-
parisons of groups were performed using Mann-Whitney tests plus
the Bonferroni correction for multiple comparisons. For the in vitro
assays, data were log transformed prior to ANOVA analysis to
equalize variances and pairwise comparisons were made using
Bonferroni’s Multiple Comparison Tests. The null hypothesis was
rejected when P was greater than or equal to 0.05.
Results
A component of adaptive immunity reduces gene
transfer with HDA vectors
A first generation adenovirus serotype 5 vector encoding firefly
luciferase under the early CMV promoter (Vector Biolabs,
Philadelphia, USA) is known to selectively transduce hepatocytes
giving rise to quantifiable bioluminescence. As can be seen in
Figure S1A (left panel) it was repeatedly observed that the level of
gene transfer upon i.v. injection of 561010 vp/mouse was higher in
T and B cell deficient Rag1KO mice in comparison to wild-type
(WT) syngeneic mice. WT animals had not been exposed to
adenovirus and were bred in Specific Pathogen-free conditions.
Data in previous reports [11,33–35] and those in Figure S1A (left
panel) conclude that the level of gene transfer upon i.v. injection of
IgM Hampers HDA Liver Transduction
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a first generation adenovirus 5 vector is higher in T and B-cell
deficient Rag1KO mice when compared to WT syngeneic mice.
To ascertain if gene transfer was the limiting factor for lower
transgene expression in WT mice, we analyzed the quantity of
adenoviral DNA vector 7 days following viral transfer. Figure S1A
(right panel) shows that quantitative PCR amplification of viral
DNA normalized by the housekeeping gene GADPH was
significantly higher in the Rag1KO mice thus pointing to less
efficient gene transfer in WT mice.
We analyzed if RagKO mice also fared better upon injection of
an HDA encoding luciferase. For this purpose, we constructed and
produced an adenovirus 5-based HDA vector encoding luciferase
under liver-specific transcriptional control which encompasses the
albumin enhancer and the alpha1-antitrypsin promoter (see
Material and Methods). Of note, this promoter has previously
been shown to be resistant to elimination or epigenetic silencing
for periods of time over 450 days ( S2). Indeed, we also observed
that Rag1KO mice expressed the reporter transgene more brightly
(Figure 1A and Figure S1B-left panel) and incorporated viral DNA
with more efficiency (Figure 1B and Figure S1B-right panel) after
the i.v. administration of 561010 HDA-luciferase vp. The decrease
in gene transfer was of the same order of magnitude for first and
third generation adenoviral vectors that only shared the capsid
proteins and suggests an innate or early adaptive function
mediated by T and/or B cells.
A function of B cells mediates gene transfer attenuation
by HDA vectors
Using mice deficient in a variety of immune system cells, we
next asked which functions played a role in the reduction of gene
transfer by HDA in WT mice. Experiments in Rag22/2IL-2c2/2
mice which are deprived of NK and NKT cells as well as B and
conventional T cells did not show any further increase in gene
transfer after i.v. administration of a dose of 561010 vp/mouse
(Figure 1A and B) ruling out a role for NK lymphocytes in the
phenotype. The other lymphocyte candidates tested were T cells
and for this purpose athymic nude mice of BALB/C background
were tested in comparison to Rag1KO, Rag22/2IL-2c2/2 and
WT mice. It was clearly observed that T-cell deficient athymic
mice had similar levels of gene transfer when compared to WT
mice thus excluding any involvement of conventional T lympho-
cytes (Figure 1A and B).
Taken together, our results indicated a key role for B cells. This
was demonstrated using B-cell deficient mice which lack the m
heavy chain gene (B6.mMT) and which, accordingly, do not
develop a mature B cell compartment [39]. In this mouse, we
observed a phenotype clearly comparable to that of Rag1KO mice
in terms of liver gene transfer by the HDA vector. It was then
assumed that an antibody-production function of B cells was
involved (Figure 1C and D).
IgM from non-immune sera reduces gene transfer by
HDA vectors
The simplest way to ascertain the involvement of antibodies was
by performing an experiment involving the passive transfer of
serum. For this purpose two doses of 400 ml of serum from non-
immunized WT mice transferred the relative resistance to HDA
liver gene transfer to Rag1KO mice of 561010 vp/mouse in a
range comparable to that observed in WT mice (Figure 2A). As
disulphide bridges in proteins can be disrupted by reducing agents
such as b-mercaptoethanol and IgM antibodies are known to be
particularly sensitive [40], we pretreated mouse sera from naı¨ve
mice with b-mercaptoethanol 0.1M at 37uC for 30 min and found
that its ability to transfer resistance against HDA gene transfer was
abolished (Figure 2A).
Our next question was which serum component related to B
cells was responsible for our observations. Affinity purification of
antibody subclasses was performed using commercially available
kits and passive transfer of two doses of 130 mg of purified IgG and
IgM from naı¨ve WT mice to Rag1KO mice. The results in
Figure 2B clearly show that the partial inhibition of gene
transduction was transferred with the polyclonal IgM fraction
but not by the polyclonal IgG fraction. Furthermore, the IgM
fraction also rescued the HDA-mediated gene transfer inhibition
in mice deficient in B cells as observed in knock-out animals for the
m heavy chain (Figure 2C).
Given the fact that all the animals were adenovirus naı¨ve, our
results indicate that either natural antibodies or an innate (non-
adaptive) function of IgM mediates this phenomenon.
Monoclonal IgM of known specificity distinct to
adenovirus reduces HDA genome uptake in vitro
To determine if HDA gene transfer reduction by IgM was a
function of natural anti-adenovirus antibodies raised in the
absence of immunization or the result of an innate function of
IgM, we made use of a mouse monoclonal IgM recognizing
human AE2 anion exchanger obtained from a conventional clonal
hybridoma (see methods) free of bovine IgM and totally unrelated
to adenovirus capsid antigens.
It was found that both polyclonal IgM from serum and
monoclonal IgM from the anti-AE2 hybridoma inhibited in vitro
gene transfer of the Huh7 hepatocellular carcinoma cell line
mediated by the luciferase encoding HDA (2.561010vp/condi-
tion). A decrease in the HDA genome uptake was also observed
when IgM was compared with monoclonal IgG- in this in vitro
assay, although statistical significance was only reached with
monoclonal IgM (Figure 3). In order to provide a molecular
explanation, we performed an ELISA (Figure 4A and B) to
determine if HDA capsids adsorb IgM antibodies. It was observed
that both monoclonal and polyclonal IgM bind adenoviral capsids,
whereas monoclonal IgG showed almost no binding to HDA
(Figure 4A). Non-immune serum showed similar levels of
polyclonal IgM binding to HDAs capsids in the ELISA assays
(Figure 4B).
Another corollary of the critical involvement of B cells is that we
could test if depletion of this subset in adult mice would rescue
more efficient gene transfer (Figure S3A). For this purpose, we
performed extensive depletions of CD20 lymphocytes (Figure S3B)
with a specific monoclonal antibody. Depletion did not reduce IgG
serum concentrations, while IgM was only decreased to about one
half of the original concentration (Figure S3C and D). However,
almost complete B cell depletion under these conditions was not
able to rescue gene transfer, implying that the remaining IgM
concentration was sufficient to inhibit gene transfer.
Monoclonal unspecific IgM reduces in vivo gene transfer
with HDA
We next tested if the monoclonal IgM antibody of unrelated
specificity also mediated gene transfer inhibition in vivo, when
passively transferred to immunoglobulin deficient Rag1KO mice.
Two doses of 130 mg of purified IgM antibody were administered
24 h and 2 h before 561010 vp of HDA-luciferase. The injection of
monoclonal IgM curtailed HDA gene transfer in terms of
luciferase activity and DNA content in the liver (Figure 5). This
inhibitory effect of monoclonal IgM was more prominent when a
relatively high i.v. dose of HDA was used (Figure 5B and C).
IgM Hampers HDA Liver Transduction
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Luciferase expression in the liver was reduced by 42% and 27% in
mice i.v. injected with 3.661010 vp/mouse and 2.261010 vp/
mouse of HDA-luciferase, respectively. Furthermore, vector DNA
content was reduced by 55% or 36% in the liver of IgM treated-
Rag1KO mice injected with either high or low doses of the HDA
vector as measured seven days after vector administration. These
data suggested that the deleterious effect of IgM is more prominent
with relatively high therapeutic doses HDA.
Finally, the polyclonal IgM activity to interfere with HDA gene
transfer was compared to that of monoclonal IgM and IgG in
Rag2KO mice (Figure 6). For this purpose, mice were injected
with a HDA carrying the human porphobilinogen deaminase gene
Figure 1. B cells are responsible for the reduction of liver gene transfer efficiency. A) Bioluminescence experiments, assessing in vivo
luciferase activity in the liver region of mice injected i.v. with HDA encoding luciferase under a liver specific promoter (561010 viral particles/mouse)
48 h prior the luciferase measurement assay (similar differences were observed on days 4 and 6 -data not shown-). Mice were WT BALB/C mice or
belonged to the indicated mutant strains in the background. The table under the graph indicates the immune cells absent in each modified strain. B)
Relative plasmid DNA content measured by Quantitative PCR in the liver of mice shown in A excised on day 7 following vector administration. C) In
vivo luciferase expression in the C57/BL6 mouse strain including WT, Rag1KO and mMT-KO mice that are selectively deficient in B cells. D) Experiments
in mice shown in C performed to quantify viral DNA content in the liver as in B. WT, Wild-type; Rag1KO, BALB/C Rag12/2 (C.129S7(B6)-Rag1tm1Mom/J;
Rag2KO, BALB/C-Rag2/2IL-2Rc2/2BALB/C; B6mMT, (B6.129S2-Ighmtm1Cgn/J; B6.Rag1KO, Rag12/2 B6 (B6.129S7-Rag1tm1Mom/J, NKs, natural killer; IgG,
immunoglobulin G; HDA-luc, helper-dependent adenoviral vectors encoding luciferase. Experiments were performed twice.
doi:10.1371/journal.pone.0085432.g001
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using the same promoter used in HDA-luciferase [23]. This vector is
more relevant as it is intended for treatment of acute intermittent
porphyria. Results in figure 6 support that passive transfer of both
monoclonal IgM of irrelevant specificity and non-immune
polyclonal IgM strongly restrain gene transfer to the liver of
Rag2KO mice in terms of enzyme activity in liver tissue
homogenates (Figure 6, left panel) and transgene DNA content
(Figure 6, right panel). In conclusion, an innate and antigen-
unspecific function of IgM limits the efficiency of gene transfer by
HDA vectors including those intended for liver gene transfer in
clinical trials.
Discussion
Optimization of gene transfer to the liver by recombinant
gutless adenovirus is perceived as an opportunity for gene therapy
for a broad spectrum of diseases [3–6,41,42]. Given the potential
inflammatory complications of high doses of viral particles
[15,9,10,17,43] drastically decreasing dose requirements
[1,2,6,19,21–23] is an important objective in successful clinical
translation. The innate response to adenoviral capsid is clearly
complex and multifactorial [7,8,10]. In pre-immunized animals,
antibodies binding to adenovirus contribute to the acute toxicity
by opsonizing adenoviral particles and rendering them more
susceptible to Fc-mediated uptake and clearance by liver
macrophages [12,13,29].
In this study we sought to examine one such limiting factor,
namely the ability of normal serum from non-immunized animals
to prevent adenoviral vector infection and liver gene transfer. A
methodical quest was initiated that concluded that B lymphocytes
were necessary and that an immunoglobulin component was
involved. Fractionation of serum experiments conclusively showed
that IgM was to blame for the unwanted inhibitory effect.
Importantly a monoclonal IgM specific for a human ion channel
and totally unrelated to adenovirus capsids also produced this
partial inhibition of gene transfer. Therefore we attribute this
limiting factor to an inherent non-adaptive protein function of
IgM. Results from previous reports [11,29,32] also show that
serum polyclonal IgM binds adenovirus 5 capsids and hampers
gene transfer. Our study demonstrates that there is no involvement
of antigen specificity but an effect related to an innate function of
IgM, also present in a monoclonal IgM that is not specific for
adenovirus. Such an interpretation is further supported by the fact
that another mouse monoclonal IgM directed to an unrelated
glycosil-phosphatidylinositol-related antigen also binds to adeno-
Figure 2. IgM mediates the mitigation of liver gene transfer by
a HDA vector. A) Rag1KO mice were passively i.v. transferred with
serum of non-immunized WT mice or similar serum samples reduced by
b-mercaptoethanol. Level of gene transfer of WT mice is provided as a
control. Liver gene transfer of luciferase by HDA vector (dose of 561010
viral particles/mouse) was assessed by bioluminescence as in Figure 1.
B) Experiments as in A but passively transferring 2 doses of 130 mg of
IgG and IgM (both purified by affinity chromatography from serum) or
400 ml of serum from WT mice. C) B6.mMT-KO mice were passively
transferred i.v. with 2 doses of 130 mg of serum IgM purified by affinity
chromatography and analyzed for liver gene transduction as in A. Wild-
type, WT; Rag1KO, BALB/C Rag12/2 (C.129S7(B6)-Rag1tm1Mom/J; B6.mMT,
(B6.129S2-Ighmtm1Cgn/J; B6.Rag1KO, pIgG, polyclonal immunoglobulin
G; pIgM, polyclonal immunoglobulin M; HDA-luc, helper-dependent
adenoviral vectors encoding luciferase. Experiments were performed
twice.
doi:10.1371/journal.pone.0085432.g002
Figure 3. Monoclonal IgM inhibits gene transfer of Huh7
hepatocellular carcinoma cells. In vitro gene transfer of 2.561010 vp
of HDA-luciferase to Huh7 cells (MOI 50.000) in the presence of 2% fetal
bovine serum and 5 mg of monoclonal IgM (mIgM) directed to an
irrelevant antigen (non crossreactive human AE2 transporter), mono-
clonal IgG which specifically recognized human interferon alpha-5 or
serum polyclonal IgM from adenovirus naı¨ve mice (pIgM) as indicated.
Relative content of vector DNA was assessed by real time PCR in
quadruplicate samples. pIgM, polyclonal immunoglobulin M; mIgM,
monoclonal immunoglobulin M, mIgG, monoclonal immunoglobulin G;
HDA-luc, helper-dependent adenoviral vectors encoding luciferase. The
experiment was repeated three times.
doi:10.1371/journal.pone.0085432.g003
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viral capsids in ELISA assays and reduces liver gene transfer in vivo
(data not shown). These findings make the interpretation of
antibody cross-reactivity very unlikely, although we cannot
definitively exclude it. The IgM region responsible for this activity
remains to be mapped.
IgM is present in high concentrations in blood. It has a relatively
short half-life in the serum, approximately 28 hours, in normal
mice in the absence of antigen [24]. It makes evolutionary sense
that IgM would host biological properties that would deal with
early infection [24,26] following virus inoculation or the first
rounds of viral replication.
Little is known about the exact mechanisms accounting for our
observations of gene transfer reduction. We have shown adsorp-
tion of adenovirus 5 capsids to serum IgM or monoclonal IgM but
subsequent molecular events leading to gene transfer inhibition
remain to be elucidated. IgM can fix and activate complement
through the classical route of activation and create C3 fragments
that would opsonize particles for their intake by phagocytes
including liver macrophages [11,30]. As the most abundant capsid
protein, most neutralizing antibodies are directed to hexon
protein. Antibodies also appear to neutralize the adenovirus not
by blocking viral entry (antibodies against fiber) but instead by
blocking microtubule transport of the virus to the nucleus after it
escapes from endosomes (hexon-targeted antibodies) [44]. Evi-
dence have been published showing that complement limits gene
transfer by an adenovirus 5-based first generation adenoviral
vector and that role is played by IgM from non-immunized mice
in this effect [11,29,32]. Factor X of coagulation has been shown
to bind adenovirus 5 capsid and protect it from attack by the
classical complement pathway. As yet we have not addressed
complement involvement but we have extended these observations
of IgM-mediated inhibition of first generation adenoviral vectors
to HDA vectors.
It must be considered that both our observations and those by
Xu et al. [32] have been made with serotype 5 adenoviral vectors
and it remains to be seen if this is a general property applicable to
other serotypes. Khare et al [11] showed that engineered
adenovirus 5 bearing the hexon from adenovirus serotype 6 may
bind IgM or other immunoglobulins but evades its clearance by
Kupffer cells. Mapping such an activity to subregions in the IgM
constant region would be of great interest, but it is a difficult
endeavor due to the fact that it is likely that both adsorption to
adenovirus and complement activation would be required in the
same moiety that needs to remain properly structured in heavy
and light chains. We have observed that disruption of IgM with
disulphide-bridge reducing agents inhibits its ability to reduce
adenoviral gene transfer. We are currently exploring if non-
specific multimeric IgM, the predominant form in plasma, can
physically aggregate adenoviral capsids and thereby conceivably
inhibit gene transfer.
Our early attempts to improve transfer by B-cell depletion with
anti-CD20 mAbs failed because of the half-life of IgM and its
production by CD20-negative plasma cells [45]. Indeed, attaining
improvement with these approaches will be very difficult because
polyclonal IgM quantities much lower than the total plasma
content in WT mice (approximately 10–15%) greatly rescue the
inhibition in Rag-deficient mice. In this sense 400 microliters of
WT serum (approximately one fourth of the total serum in the
mouse) transferred to immunodeficient mice hampered gene
transfer to the level observed in B-cell immunocompetent mice.
Other strategies to reduce IgM levels prior to gene-therapy
treatment in humans should be suitable. These include plasma-
pheresis [46] that would reduce both IgM and complement
factors. This procedure is difficult to test in rodents. If the
protective role of factor X is critical [32], providing an additional
supply even directly into the suspension of HDA vector prior to
injection may be an interesting option. Our in vitro gene transfer
experiments to Huh7 cells were performed in the presence of 2%
complement-inactivated bovine serum and under such conditions
monoclonal IgM decrease gene transfer by the HDA vector.
Probably in this setting IgM antagonizes interactions with viral
receptors. This in vitro assay provides a simple model to study the
Figure 4. IgM antibodies bind adenoviral capsids. ELISA tests performed on HDA-luciferase coated 96-well plates sequentially incubated with
the indicated antibodies and secondary antibodies. Results are presented as absorbance at 450 nm 6 standard deviation at the time of stopping the
reaction. A) Binding of the indicated polyclonal non-immune IgM and the monoclonal hybridoma-produced IgM and IgG were tested for their ability
to bind capsids and were revealed with the proper subclass specific secondary reagents. B) ELISA Experiments as in A extending the developing time
to detect potentially weaker interactions and testing WT and Ig-free Rag1KO serum as well as monoclonal IgG and IgM. The background reactivity of
secondary antibodies was virtually non-existent. Wild-type, WT; Rag1KO, BALB/C Rag12/2 (C.129S7(B6)-Rag1tm1Mom/J; pIgM, polyclonal
immunoglobulin M; mIgM, monoclonal immunoglobulin M, mIgG, monoclonal immunoglobulin G. Experiments were repeated twice in replicates
and statistical comparisons were performed as described in Materials and Methods section.
doi:10.1371/journal.pone.0085432.g004
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Figure 5. Monoclonal IgM of a specificity unrelated to adenovirus reduces liver gene transfer by HDA vectors. A) Representative
photographs of light emission from the liver region of mice intravenously injected with 561010 vp/mouse 48 h prior to bioluminescence (left panel).
When indicated, Rag1KO were pre-injected twice with 130 mg of monoclonal IgM of irrelevant specificity. The dot graph on the right shows
quantitative data from the same experiment. Experiments B and C were performed seven days following gene transfer with progressively reduced
doses of HDA-luciferase (3.661010 vp/mouse and 2.26109 vp/mouse, respectively). Gene transfer was assessed by measuring luciferase activity ex-
vivo in homogenates from liver samples (left panel). The relative liver content of vector DNA was measured by quantitative PCR (right panel). WT,
Wild-type; Rag1KO, BALB/C Rag12/2 (C.129S7(B6)-Rag1tm1Mom/J; pIgM, polyclonal immunoglobulin M; mIgM, monoclonal immunoglobulin M, mIgG,
monoclonal immunoglobulin G.; HDA-luciferase, helper-dependent adenoviral vectors encoding luciferase; RLU, Relative Light Unit. Experiments were
performed twice.
doi:10.1371/journal.pone.0085432.g005
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molecular requirements for complement and coagulation factors
and to devise strategies to counteract the innate inhibitory role of
IgM antibodies for efficient gene transfer by HDA.
As a whole, our data show that IgM has innate immunity
functions. These biological properties confer sufficient avidity to a
wide range of viruses and viral vectors, thus constituting a
mitigating factor for viral infection but also a perhaps a removable
hurdle for gene transfer. In particular, IgM is an important
obstacle for gene therapy with HDA vectors.
Supporting Information
Figure S1 The adaptive immune system decreases liver
gene transfer efficiency by recombinant adenoviral
vectors. A) The indicated WT numbered strain of mice were
intravenously injected with 46109 plaque-forming units of
AdCMV-luciferase/kg and monitored 24 h later for luciferase
expression in the liver region (left panel) and vector DNA content
by quantitative PCR (right panel). AdCMV-luciferase is an E1, E3-
deleted replication-deficient adenoviral vector expressing firefly
luciferase under the control of the cytomegalovirus promoter
(Vector Biolabs, Philadelphia, PA). B) Similar assays as in A but
using a third generation helper-dependent adenoviral vector
expressing luciferase under a liver-specific promoter (561010 viral
particles of HDA-luciferase/mouse). The non-parametric Mann–
Whitney U-test was used for comparison of two groups (GraphPad
Prism software, Graphpad Software Inc., La Jolla, CA, USA). The
results were presented as the interquartile range (box) and the
extreme values (whisker). The null hypothesis was rejected when P
was greater than or equal to 0.05. WT, wild type; Rag1KO,
Rag12/2 BALB/C (C.129S7(B6)-Rag1tm1Mom/J; Ad-Luc, first
generation adenoviral vector expressing firefly luciferase; HDA-
luciferase, helper-dependent adenoviral 5 vectors encoding lucifer-
ase.
(TIF)
Figure S2 Duration of liver gene transfer in a cohort of 5
wild-type BALB/c mice injected intravenously with
561010 viral particles/mouse of HDA-luciferase. Lucifer-
ase expression was periodically monitored up to 450 days using a
Xenogen IVIS bioluminescence imaging system (Xenogen,
Alameda, CA) which includes a cooled charge-coupled device
(CCD) camera. HDA-luciferase, helper-dependent adenoviral 5
vectors encoding luciferase. The results were expressed as the
mean 6 standard deviation.
(TIF)
Figure S3 B-cell depletion with anti-CD20 mAb does not
increase gene transfer most probably due to small
reductions in serum IgM concentration. B cell depletion
for 3 weeks with anti-CD20 mAb (mouse analogue to rituximab)
did not increase HDA-mediated luciferase liver gene transfer in
female BALB/C wild type mice (A) in spite of extensive reductions
in B cells in the spleen (B). FACSCalibur (BD-Biosciences, San
Agustı´n de Guadalix, Spain) was used for cell acquisition and data
analysis was carried out using FlowJo software (Tree Star Inc.,
Olten, Switzerland). Follow up of immunoglobulin concentrations
showed only 30–40% decreases in serum concentrations of IgM
(C) without changes in serum IgG (D). The results were presented
as the interquartile range (box) and the extreme values (whisker).
Data were log transformed prior to one-way ANOVA analysis to
equalize variances and pairwise comparisons were made using
Bonferroni’s Multiple Comparison Tests. The null hypothesis was
rejected when P was greater than or equal to 0.05. WT, wild type;
Rag1KO, Rag12/2 BALB/C (C.129S7(B6)-Rag1tm1Mom/J); anti-
CD20, Antimouse-CD20 antibody; HDA-luciferase, helper-depen-
dent adenoviral 5 vectors encoding luciferase.
(TIF)
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Figure 6. In vivo gene transfer of a HDA encoding PBGD is inhibited by monoclonal and polyclonal IgM. Gene transfer with a HDA vector
intended for the correction of acute intermittent porphyria were performed in Rag2KO mice or control WT mice. Immunoglobulins were injected 24 h
and 2 h before the infusion of 561010 vp/mouse of HDA-PBGD. PBGD enzymatic activity in liver homogenates obtained 48 h after gene transfer (left
panel) and PBGD transgene relative DNA content to GADPH by quantitative PCR (right panel). WT, Wild-type; Rag2KO, Rag2/2IL-2Rc2/2; pIgM,
polyclonal immunoglobulin M; mIgM, monoclonal immunoglobulin M, mIgG, monoclonal immunoglobulin G; HDA-PBGD, helper-dependent
adenoviral vectors encoding human porphobilinogen deaminase.
doi:10.1371/journal.pone.0085432.g006
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